20191
document
Efficacy , safety , and steady-state pharmacokinetics of once-a-day controlled-release morphine ( MS Contin XL ) in cancer pain . The efficacy , safety , and pharmacokinetics of a novel once-daily morphine formulation ( OAD morphine ) and a 12-hourly formulation ( twice-daily CR morphine ) were compared in a double-blind , multi-centered crossover study . Chronic cancer pain patients ( n=25 ) were randomized to OAD morphine ( mean 238 +/- 319 mg q24h ) or twice-daily CR morphine ( mean 119 +/- 159 mg q12h ) for one week . They then crossed over to the alternate drug , which also was taken for one week . There was no difference between treatments for evaluations of overall pain intensity , analgesic efficacy , or adverse events . However , whereas pain scores increased during the day on twice-daily CR morphine ( P=0.0108 ) , they remained stable on OAD morphine . Most patients ( 68 % ) chose once-daily dosing for continuing pain management ( P=0.015 ) . The AUC ratio was 100.3 % , indicating equivalent absorption . Fluctuation indices were 93.5 +/- 28.8 % and 179.3 +/- 41.3 % ( P=0.0001 ) for OAD morphine and twice-daily CR morphine , respectively . OAD morphine provides analgesia similar to twice-daily CR morphine with reduced fluctuation in plasma morphine concentration and more stable pain control .
20192
Intervention_Pharmacological
morphine
20193
Intervention_Pharmacological
morphine formulation ( OAD morphine )
20194
Intervention_Pharmacological
morphine
20195
Intervention_Pharmacological
OAD morphine
20196
Intervention_Pharmacological
twice-daily CR morphine
20197
Intervention_Pharmacological
morphine
20198
Intervention_Pharmacological
morphine
20199
Intervention_Pharmacological
morphine
20200
Intervention_Pharmacological
morphine
20201
Outcome_Other
Efficacy , safety , and steady-state pharmacokinetics
20202
Outcome_Other
efficacy , safety , and pharmacokinetics
20203
Outcome_Pain
overall pain intensity
20204
Outcome_Other
analgesic efficacy
20205
Outcome_Adverse-effects
adverse events
20206
Outcome_Pain
pain scores
20207
Outcome_Pain
pain management
20208
Outcome_Other
AUC ratio
20209
Outcome_Other
Fluctuation indices
20210
Outcome_Physical
fluctuation in plasma morphine concentration
20211
Outcome_Pain
pain control
20212
Participant_Condition
cancer pain
20213
Participant_Condition
Chronic cancer pain
20214
Participant_Sample-size
n=25